Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.68, Iss.2, 2001-07, pp. : 101-110

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, ^3H-thymidine labelling index (TLI), c-erbB-2 and p27^kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were treated with surgery ± radiotherapy and adjuvant tamoxifen (30 mg/day) for at least 2 years. TLI, ER, c-erbB-2 and p27^kip1 were generally unrelated to each other. PgR was directly related to ER and inversely to c-erbB-2. Tumour size was inversely related to both c-erbB-2 and p27^kip1 expression. At a median follow-up of 75 months, 5-year relapse-free survival was significantly lower for patients with very rapidly proliferating (HR = 2.61, 95% CI = 1.34–5.08), PgR negative (HR = 2.76, 95% CI = 1.43–5.33) or relatively low ER content (HR = 2.20, 95% CI = 1.14–4.25) tumours than for patients with tumours expressing the opposite biological profiles. Overall survival was also significantly different as a function of TLI (HR = 3.47, 95% CI = 1.52–7.93) and PgR (HR = 2.27, 95% CI = 1.00–5.15). TLI and PgR maintained an independent relevance in multivariate analysis and together were capable of identifying subgroups of patients at significantly different risk of relapse and death.